Also published in GlobeNewswire:
NACD Directorship 100 Forum Focused on Reinvigorating America
x hide permanently

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors


Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors...

Mentions: Nasdaq Arvinas Board of Directors